- Home
- PAVM vs ONCO Comparison
PAVM vs ONCO Comparison
Compare PAVM & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | ONCO |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.1M | 755.3K |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAVM | ONCO |
|---|---|---|
| Price | $9.27 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $65.00 | N/A |
| AVG Volume (30 Days) | 10.0K | ★ 12.7M |
| Earning Date | 05-14-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | $603.94 | N/A |
| Revenue Next Year | $64.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.21 | $0.05 |
| 52 Week High | $28.44 | $7.65 |
Technical Indicators
Market Signals| Indicator | PAVM | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 42.77 |
| Support Level | $8.47 | $0.51 |
| Resistance Level | $10.98 | $0.95 |
| Average True Range (ATR) | 0.44 | 0.72 |
| MACD | -0.06 | -0.11 |
| Stochastic Oscillator | 51.39 | 0.83 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.